Related Experiment Videos
Vaginal Candida albicans treated with three different concentrations of natamycin (Pimafucin) for 6 days
Abstract:
In 88 patients with vaginal Candida albicans a treatment was performed with natamycin vaginal cream for 6 days in daily doses of 5 ml at concentrations 25 mg natamycin/5 ml (Pim-25), 50 mg natamycin/5 ml (Pim-50), and 100 mg natamycin/5 ml (Pim-100). The cure rates, assessed according to negative cultures of swabs 4-7 days after discontinuation of the treatment, were 89.3%, 85.7%, and 96.9% respectively. Swabs taken about 2 weeks after the next menstrual period showed cure rates of 67.9%, 67.9%, and 78.1% respectively. There was no statistically significant difference in the results between the three groups at the 5% level in Fisher's exact test. The recurrence rate was high in all three groups.
Insights
Natamycin vaginal cream effectively treated vaginal Candida albicans infections, with cure rates up to 96.9%. However, high recurrence rates were observed across all tested concentrations, indicating a need for further research into long-term efficacy.
Area of Science:
- Mycology
- Pharmacology
- Gynecology
Background:
- Vaginal candidiasis, often caused by Candida albicans, is a common fungal infection.
- Natamycin is an antifungal agent used in treating various fungal infections.
Purpose of the Study:
- To evaluate the efficacy and recurrence rates of different concentrations of natamycin vaginal cream for treating vaginal Candida albicans infections.
- To compare the cure rates of three natamycin concentrations: Pim-25 (25 mg/5 ml), Pim-50 (50 mg/5 ml), and Pim-100 (100 mg/5 ml).
Main Methods:
- A treatment study involving 88 patients diagnosed with vaginal Candida albicans.
- Patients received 5 ml of natamycin vaginal cream daily for 6 days at concentrations of 25 mg/5 ml, 50 mg/5 ml, or 100 mg/5 ml.
- Cure rates were assessed via negative cultures 4-7 days post-treatment and again after the following menstrual period.
Main Results:
- Initial cure rates 4-7 days after treatment were high, ranging from 85.7% to 96.9% across the three groups.
- Cure rates approximately two weeks after the next menstrual period decreased, ranging from 67.9% to 78.1%.
- No statistically significant difference in cure rates was found between the three natamycin concentrations at the 5% significance level.
Conclusions:
- Natamycin vaginal cream demonstrates high initial efficacy in treating vaginal Candida albicans.
- The study observed a high recurrence rate of vaginal candidiasis despite treatment with natamycin.
- Further investigation is warranted to address the high recurrence rates and optimize long-term management strategies for vaginal candidiasis.